Incysus Seeks OK to Begin Phase 1 Trial of Gamma-delta T-cell Immunotherapy for GlioblastomaImmuno-Oncology NewsIncysus has submitted its second investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a … Continue reading
Global challenge calls on youth to tackle food securityFarm ForumPrevious entries have covered key areas such as vertical farming, logistics, breeding, agtech, open data, aquaculture and livestock, food waste, synthetic biology, new proteins and approp… Continue reading
Global challenge calls on youth to tackle food securityFarm ForumPrevious entries have covered key areas such as vertical farming, logistics, breeding, agtech, open data, aquaculture and livestock, food waste, synthetic biology, new proteins and approp… Continue reading
Industry report – CRISPR: the gene editing tool making the world go roundIAM (blog)The battle over clustered regularly interspaced short palindromic repeat (CRISPR) technology between Feng Zhang and the Broad Institute at the Massachusetts Institute of… Continue reading
|
The HLF gene protects blood stem cells by maintaining them in a resting state
EurekAlert (press release) “The study confirms several previous studies that show the HLF gene’s significance in blood formation”, says Mattias Magnusson who led the new study. The results can have important applications in bone marrow transplants, as well as contribute to our … |
The Weekly Standard |
Can Pricey Immunotherapy Drugs Help Fight Infectious Disease in Developing Countries?
The Weekly Standard One of the high-tech therapies described by Gates was cancer immunotherapy, which involves using chemicals or even genetic modifications to stimulate the body’s immune system to attack tumors. While often very effective at treating cancers that have … |
Philadelphia Business Journal |
Price for Spark gene therapy too high, ICER says
BioPharma Dive Spark Therapeutics Inc.’s newly approved gene therapy for a rare form of blindness is too expensive to be considered cost-effective, according to a new report from a research organization known for its critiques of industry pricing practices. Currently … Nonprofit agency says Spark’s gene therapy $425K price tag is too highPhiladelphia Business Journal ICER report critical of Spark Therapeutics’ pricing of LuxturnaThe Pharma Letter |